Increasing Access to Early Diagnosis and Assessment of Autism Via Biomarker-Based Measurements of Social Visual Engagement.
FDA-cleared eye-tracking can diagnose autism under three, but only if you redesign your clinic flow first.
01Research in Context
What this study did
Klin (2025) lays out a plan to spot autism before age three with FDA-cleared eye-tracking tests. The paper is a call to action, not a lab study. It says we must change how clinics work so the new tool can reach families fast.
What they found
The author shows the biomarker is ready but our service system is not. Long wait lists and travel barriers keep most toddlers from getting an early label. Without new delivery models, the tech alone will not cut wait times.
How this fits with other research
Schultz (2008) first dreamed of brain-based autism markers; Ami now says eye-tracking has crossed the finish line with real FDA clearance. McGee et al. (2019) gives the map: use behavioral systems analysis to re-shape intake, training, and billing before the devices arrive. Fusaroli et al. (2022) proves vocal markers also work but only at small effect sizes, while eye-tracking claims bigger accuracy, suggesting visual tools may leap ahead of audio ones. Bast et al. (2022) shows eye metrics work in adults for memory; Ami moves the same camera down to babies for diagnosis, extending the method to a new age and purpose.
Why it matters
You can shorten your clinic's 18-month wait today by prepping the system, not just buying gear. Plot each step families take now, remove one non-value-added step per month, and train staff on eye-tracking scripts so the tool slots in the day it arrives. Early diagnosis without early service change is just another empty promise.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Map your current intake process, pick one redundant step to cut this week, and slot 'eye-tracking session' into the flow on paper.
02At a glance
03Original abstract
Only one in every five children with autism is diagnosed before the age of 3 years. As a result, tens of thousands of children every year in the United States miss benefiting from early interventions and supports that could potentially optimize their lifetime outcomes. A major obstacle is the extremely limited access to high quality diagnosis. To address this challenge, biomarker-based objective procedures for early diagnosis and assessment of autism have already been clinically validated and cleared for broad implementation by the U.S. Food and Drug Administration. Broad community uptake of these science-based solutions, however, will require change in entrenched models of diagnostic care, and aggressive prioritization of the needs of the community at large.
American journal on intellectual and developmental disabilities, 2025 · doi:10.1352/1944-7558-130.3.167